Double or Single Dose Sirolimus-Eluting Stents in Diabetic Patients With de Novo Coronary Artery Lesions

Inclusion Criteria: 1. The patient must be minimum 18 years of age; 2. Patients must be previously diagnosed with diabetes with documented treatment with insulin, oral medications, or diet for a minimum of 3 months; 3. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II-III) OR patients with documented silent ischemia; 4. Treatment of one lesion in a native coronary artery. The treated lesion will be the one with the highest % diameter stenosis by visual estimate. Additional study stents may be used for procedural complications such as dissections. Multivessel treatment is permissible in non-target vessels; however, additional lesions may only be treated with commercial stents. If other non-target lesions are treated with commercial stents during the index procedure, they must be successfully treated prior to the study lesion; 5. The target vessel is 2.5 mm and 3.5mm in diameter (visual estimate); 6. The target lesion is \<30 mm in length (visual estimate) located in a native coronary artery; 7. Target lesion stenosis is \>50% and \<100% (TIMI I) (visual estimate); Exclusion Criteria: 1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK\>2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remains above normal at the time of treatment; 2. Patients admitted for treatment of diabetic ketoacidosis \> 2 times in the past six months (Brittle Diabetics); 3. Ejection fraction 30%; 4. Impaired renal function (creatinine \> 2.0 mg/dL);